Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | NR5A2 | O00482 | 1/20 | 0.53 |
| ▸ | NR5A1 | Q13285 | 1/20 | 0.53 |
| ▸ | RECQL | P46063 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | ESR1 | P03372 | 1/20 | 0.47 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.47 |
| ▸ | CDC25A | P30304 | 1/20 | 0.47 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.47 |
| ▸ | AKT1 | P31749 | 1/20 | 0.47 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
| ▸ | DAGLA | Q9Y4D2 | 1/20 | 0.46 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.46 |
| ▸ | PTAFR | P25105 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL479222 | 1.00 | ALDH1A1 (0.60) | ALDH1A1SMN1; SMN2NR5A2NR5A1RECQL | |
| SCHEMBL479388 | 1.00 | ALDH1A1 (0.60) | ALDH1A1SMN1; SMN2NR5A2NR5A1RECQL | |
| SCHEMBL479198 | 1.00 | ALDH1A1 (0.60) | ALDH1A1SMN1; SMN2NR5A2NR5A1RECQL | |
| SCHEMBL37559 | 1.00 | ALDH1A1 (0.60) | ALDH1A1SMN1; SMN2NR5A2NR5A1RECQL | |
| SCHEMBL671456 | 1.00 | ALDH1A1 (0.60) | ALDH1A1SMN1; SMN2NR5A2NR5A1RECQL | |
| SCHEMBL4619726 | 0.97 | ALDH1A1 (0.64) | ALDH1A1SMN1; SMN2NR5A2NR5A1RECQL | |
| SCHEMBL4619498 | 0.97 | ALDH1A1 (0.64) | ALDH1A1SMN1; SMN2NR5A2NR5A1RECQL | |
| SCHEMBL479563 | 0.97 | ALDH1A1 (0.64) | ALDH1A1SMN1; SMN2NR5A2NR5A1RECQL | |
| SCHEMBL479610 | 0.97 | ALDH1A1 (0.64) | ALDH1A1SMN1; SMN2NR5A2NR5A1RECQL | |
| SCHEMBL1576782 | 0.96 | ALDH1A1 (0.66) | ALDH1A1SMN1; SMN2NR5A2NR5A1RECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 133 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025056467-A1 | POLYPHOSPHOESTER STABILIZING AGENTS, COMPOSITIONS, USES, AND MANUFACTURING METHODS THEREOF | GLOBAL LIFE SCIENCES SOLUTIONS CANADA ULC (CA) | 2025-03-20 | — | — | WO | claimed |
| WO-2025056466-A1 | POLYVINYLPYRROLIDONE STABILIZING AGENTS, COMPOSITIONS, USES, AND MANUFACTURING METHODS THEREOF | GLOBAL LIFE SCIENCES SOLUTIONS CANADA ULC (CA) | 2025-03-20 | — | — | WO | claimed |
| WO-2024006960-A1 | LIPID NANOPARTICLES FOR DELIVERY OF NUCLEIC ACIDS | JUNO THERAPEUTICS, INC. (US) | 2024-01-04 | — | — | WO | claimed |
| WO-2023242827-A2 | LIPID NANOPARTICLES (LNPs)-BASED OCULAR DELIVERY | CRISPR THERAPEUTICS AG (CH) | 2023-12-21 | — | — | WO | claimed |
| WO-2020047141-A1 | OPHTHALMIC INJECTABLE FORMULATION PREPARING AND OCULOPATHY TREATING AND PREVENTING | LIU YUNXIANG (US) | 2020-03-05 | — | — | WO | claimed |
| EP-3458083-A1 | POLYNUCLEOTIDES ENCODING INTERLEUKIN-12 (IL12) AND USES THEREOF | Modernatx, Inc. (US) | 2019-03-27 | — | — | EP | claimed |
| EP-3458092-A1 | MRNA COMBINATION THERAPY FOR THE TREATMENT OF CANCER | Modernatx, Inc. (US) | 2019-03-27 | — | — | EP | claimed |
| EP-3302436-A1 | LIPOSOMAL NANOCONSTRUCTS AND METHODS OF MAKING AND USING THE SAME | The General Hospital Corporation (US) | 2018-04-11 | — | — | EP | claimed |
| WO-2017201352-A1 | MRNA COMBINATION THERAPY FOR THE TREATMENT OF CANCER | MODERNATX, INC. (US) | 2017-11-23 | — | — | WO | claimed |
| WO-2017201350-A1 | POLYNUCLEOTIDES ENCODING INTERLEUKIN-12 (IL12) AND USES THEREOF | MODERNATX, INC. (US) | 2017-11-23 | — | — | WO | claimed |
| WO-2017184081-A1 | SUBCONJUCTIVAL DEPOT FORMING FORMULATIONS FOR OCULAR DRUG DELIVERY | NANYANG TECHNOLOGICAL UNIVERSITY (SG) | 2017-10-26 | — | — | WO | claimed |
| WO-2017125954-A1 | A PROCESS FOR DISSOCIATION OF HYDRATES IN PRESENCE OF ADDITIVES OR HYDRATE DISSOCIATION PROMOTERS | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2017-07-27 | — | — | WO | claimed |
| WO-2017004518-A1 | SITE-TARGETED NANO-LIPOSOMAL NITROGLYCERIN THERAPEUTICS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-01-05 | — | — | WO | claimed |
| WO-2016191556-A1 | LIPOSOMAL NANOCONSTRUCTS AND METHODS OF MAKING AND USING THE SAME | THE GENERAL HOSPITAL CORPORATION (US) | 2016-12-01 | — | — | WO | claimed |
| WO-2010030730-A1 | POLYETHYLENE GLYCOL LIPID CONJUGATES AND USES THEREOF | ABBOTT LABORATORIES (US) | 2010-03-18 | — | — | WO | claimed |
| WO-2009129385-A1 | CATIONIC LIPIDS AND USES THEREOF | ABBOTT LABORATORIES (US) | 2009-10-22 | — | — | WO | claimed |
| WO-2026102455-A1 | LIPID NANOPARTICLE COMPOSITIONS FOR MICRONEEDLE-BASED TRANSDERMAL DELIVERY | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2026-05-15 | — | — | WO | disclosed |
| WO-2026090590-A1 | NANOPARTICLE FORMULATIONS FOR THE DELIVERY OF DNA TO ADIPOSE TISSUE | Remedium Bio, Inc. (US) | 2026-04-30 | — | — | WO | disclosed |
| WO-2005069004-A2 | SOLID-SUPPORTED MEMBRANES INSIDE POROUS SUBSTRATES AND THEIR USE IN BIOSENSORS | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2005-07-28 | — | — | WO | disclosed |
| WO-1998034597-A1 | LIPOSOMES CONTAINING ACTIVE AGENTS | DUKE UNIVERSITY (US) | 1998-08-13 | — | — | WO | disclosed |